About
BioMAS Ltd is a clinical-stage company focusing on the invention, development, and commercialization of tellurium-based compounds. The companys lead molecules, AS101 and SAS, are small tellurium-based compounds developed for the treatment of various conditions. The molecules have integrin-inhibitory properties. Integrins are emerging therapeutic targets in many human pathologies. The companys AS101/SAS drugs have demonstrated preclinical and clinical safety and efficacy for autoimmune-inflammatory diseases (psoriasis, arthritis, Crohns, and MS), certain viral conditions (HPV warts), angiogenesis-related diseases (AMD), thrombocytopenia, neutropenia, and fertility preservation following chemotherapy and radiotherapy. A 15.4% stake in the company was acquired by Cosmo Pharmaceuticals (XSWS:COPN) for ILS 7 million on March 27, 2014.